Breast cancer survival in the US and Europe: A CONCORD high-resolution study.


Allemani, C; Sant, M; Weir, HK; Richardson, LC; Baili, P; Storm, H; Siesling, S; Torrella-Ramos, A; Voogd, AC; Aareleid, T; Ardanaz, E; Berrino, F; Bielska-Lasota, M; Bolick, S; Cirilli, C; Colonna, M; Contiero, P; Cress, R; Crocetti, E; Fulton, JP; Grosclaude, P; Hakulinen, T; Izarzugaza, MI; Malmström, P; Peignaux, K; Primic-Žakelj, M; Rachtan, J; Safaei Diba, C; Sánchez, MJ; Schymura, MJ; Shen, T; Traina, A; Tryggvadottir, L; Tumino, R; Velten, M; Vercelli, M; Wolf, HJ; Woronoff, AS; Wu, X; Coleman, MP; (2013) Breast cancer survival in the US and Europe: A CONCORD high-resolution study. International journal of cancer Journal international du cancer, 132 (5). pp. 1170-81. ISSN 0020-7136 DOI: 10.1002/ijc.27725

Full text not available from this repository. (Request a copy)

Abstract

: Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.<br/>

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
Research Centre: Cancer Survival Group
Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 22815141
Web of Science ID: 314071300020
URI: http://researchonline.lshtm.ac.uk/id/eprint/103753

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
454Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item